To include your compound in the COVID-19 Resource Center, submit it here.

Multaq dronedarone regulatory update

FDA began reviewing data from Sanofi's international Phase IIb PALLAS trial evaluating Multaq dronedarone to treat permanent atrial fibrillation

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE